Genetic Physiopathology and Evolution of Type 2 Diabetes (GENFIEV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00879801
Recruitment Status : Completed
First Posted : April 10, 2009
Last Update Posted : April 10, 2009
Italian Society of Diabetology
Eli Lilly and Company
Information provided by:
University of Pisa

Brief Summary:

There are few longitudinal studies in the Caucasian population and even less in the Italian population in subjects with impaired glucose regulation to allow:

  1. An estimate of the rate of conversion to type 2 diabetes;
  2. To identify subjects at risk; and
  3. To assess the physiopathologic mechanisms responsible for the conversion.

In order to set up a longitudinal study capable of defining the above parameters it is mandatory that the physiological, biochemical, and, genetic markers specific for IGR are identified. The goals of the present research proposal are:

  1. To clarify the physiological mechanisms responsible for IGR;
  2. To identify the biochemical and beta-cell auto-immune parameters present in IGR;
  3. Identify genetic markers.

The subjects who will be identified will add up to other 900 individuals who will be recruited as part of a follow-up program sponsored by the Italian Society of Diabetes, specifically designed to assess conversion rate to diabetes.

Condition or disease

Detailed Description:

The main goal of the present research program is to recruit about 600 new subjects with IGR to be added to the 900 subjects which are collected as part of the GENFIEV project which has been designed as a 6-yr follow-up study to ascertain the rate of conversion to type 2 diabetes in the Italian population. In particular the goal of the present research program will be to determine in a sample of the Italian population at greater risk for type 2 diabetes than the general population:

  • the pathophysiologic mechanisms responsible for the disorders of impaired glucose regulation (IGR). In particular we will evaluate insulin action and insulin secretion as a function of the degree of glucose tolerance by analyzing these parameters in normal subjects as well as in IFG/NGT, NFG/IGT, and IFG/IGT individuals;
  • the biochemical markers associated with the disorders of impaired glucose regulation (IGR). In particular we will evaluate several biochemical parameters (lipid profile, coagulative profile, microlbuminuria, free-fatty acids, PAI-1, fibrinogen, creatinine, uric acid, HbA1c);
  • the cardiovascular risk profile associated with the disorders of impaired glucose regulation (IGR). In particular, the relevant biochemical parameters will be integrated with measurements of arterial blood pressure as well as ECG recording;
  • the genetic markers associated with the disorders of impaired glucose regulation (IGR). In particular subjects will be screened for HHEX, IGF2,BP2 CDKAL1,TCF2L7, CDKN2A/B,WFS1;
  • the impact of environmental factors on the disorders of impaired glucose regulation (IGR).

Finally, we will endeavour to assess the cellular pathways that may be affected by metabolic alterations typically occurring in concomitance with the disorders of impaired glucose regulation (IGR).

Study Type : Observational
Actual Enrollment : 1017 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Genetic, Biochemical and Clinical Determinants of Type 2 Diabetes Progression in Subjects at High Risk
Study Start Date : January 2003
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Subjects with IGR
Subjects at high risk of diabetes, such as those with impaired glucose regulation (IFG and or IGT)

Primary Outcome Measures :
  1. The rate of conversion to diabetes of IGR subjects carrier of type 2 diabetes susceptibility genes [ Time Frame: December 2009 ]

Biospecimen Retention:   Samples With DNA
Serum and plasma sample, DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects will be recruited from outpatients diabetic units located in different areas of Italy.

Inclusion Criteria:

  • Each consecutive subject referred to a diabetes clinic for a diagnostic OGTT meeting the above criteria will be assessed as a potential candidate for the study till a total recruitment of 75 individuals will be reached.

    • The OGTT will be performed after an overnight fast as described below.
    • Individuals with IGT (FPG value of < 7.0 mmol/l, and 2-h PG > 7.8 and < 11.1 mmol/l), IFG (FPG > 6.1 and < 7.0 mmol/l, and 2-h PG value of < 11.1 mmol/l).
  • Subjects who had both IFG and IGT will included as well.
  • Subjects with normal glucose tolerance (FPG <6.1 and 2-h PG <7.8 mmol/l) will be also recruited as controls

Exclusion Criteria:

  • Use of drugs known to interfere with glucose metabolism (corticosteroids, beta-blockers, etc)
  • Pregnant women, women who are breast feeding
  • Active arterial disease (unstable angina, myocardial infarction, cerebrovascular accident, etc) within 3 months of trial entry
  • History of malignancy
  • Uncontrolled hypertension or hypothyroidism; history of alcohol, or drug abuse, or both
  • Active liver disease
  • Subjects tacking cyclic hormone replacement therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00879801

Department of Endocrinology and Metabolism, University of Pisa
Pisa, Italy
Sponsors and Collaborators
University of Pisa
Italian Society of Diabetology
Eli Lilly and Company

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: FoRiSID, Research Foundation of the Italian Society of Diabetology Identifier: NCT00879801     History of Changes
Other Study ID Numbers: GENFIEV
First Posted: April 10, 2009    Key Record Dates
Last Update Posted: April 10, 2009
Last Verified: April 2009

Keywords provided by University of Pisa:
prevention of diabetes
susceptibility genes
type 2 diabetes
insulin resistance
beta-cell funtion

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Prediabetic State
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases